A-498Homo sapiens (Human)Cancer cell line
Also known as: A498
Quick Overview
Human renal cell carcinoma cell line for cancer research.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1056 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Kidney[UBERON:UBERON_0002113] |
Donor Information
| Age | 52 |
|---|---|
| Age Category | Adult |
| Sex | Female |
Disease Information
| Disease | Renal cell carcinoma |
|---|---|
| Lineage | Kidney |
| Subtype | Renal Cell Carcinoma |
| OncoTree Code | RCC |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000555_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | PIK3CB | p.Asp1067Val (c.3200A>T) | Heterozygous | - | from parent cell line A-498 |
| MutationSimple | VHL | p.Gly144Serfs*14 (c.426_429delTGAC) | Homozygous | - | from parent cell line A-498 |
| MutationSimple | VHL | p.Val142fs*30 (c.425_429delTTGAC) | Unspecified | - | PubMed=8493574 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Activating mutations in PIK3CB confer resistance to PI3K inhibition and define a novel oncogenic role for p110beta.
Hampton G.M., Lackner M.R.
Cancer Res. 76:1193-1203(2016).
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection.
Hsieh J.J.-D., Hakimi A.A.
Nat. Commun. 8:15165.1-15165.10(2017).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
Choosing the right cell line for renal cell cancer research.";
Czarnecka A.M.
Mol. Cancer 15:83.1-83.15(2016).
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
Mob. DNA 7:20.1-20.11(2016).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Vandesompele J.
Sci. Data 3:160052-160052(2016).
Data for identification of GPI-anchored peptides and omega-sites in cancer cell lines.
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Data Brief 7:1302-1305(2016).
Identification of glycosylphosphatidylinositol-anchored proteins and omega-sites using TiO2-based affinity purification followed by hydrogen fluoride treatment.
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
J. Proteomics 139:77-83(2016).
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
Fogh J., Fogh J.M., Orfeo T.
J. Natl. Cancer Inst. 59:221-226(1977).
Human melanoma cells have both nerve growth factor and nerve growth factor-specific receptors on their cell surfaces.
Sherwin S.A., Sliski A.H., Todaro G.J.
Proc. Natl. Acad. Sci. U.S.A. 76:1288-1292(1979).
Human brain tumour cell strains with deficient host-cell reactivation of N-methyl-N'-nitro-N-nitrosoguanidine-damaged adenovirus 5.
Day R.S. 3rd, Ziolkowski C.H.J.
Nature 279:797-799(1979).
Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors.
Fogh J.
Natl. Cancer Inst. Monogr. 49:5-9(1978).
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
Fogh J., Wright W.C., Loveless J.D.
J. Natl. Cancer Inst. 58:209-214(1977).
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.
J. Natl. Cancer Inst. 83:757-766(1991).
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Cancer Res. 48:589-601(1988).
In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors.
Dosik H., Parks W.P.
J. Natl. Cancer Inst. 51:1417-1423(1973).
Cell culture quality control by rapid isoenzymatic characterization.
Halton D.M., Peterson W.D. Jr., Hukku B.
In Vitro 19:16-24(1983).
Repair of O6-methylguanine in DNA by demethylation is lacking in Mer- human tumor cell strains.
Yarosh D.B., Foote R.S., Mitra S., Day R.S. 3rd
Carcinogenesis 4:199-205(1983).
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
Wright W.C., Daniels W.P., Fogh J.
J. Natl. Cancer Inst. 66:239-247(1981).
Differential expression of the amv gene in human hematopoietic cells.
Aaronson S.A., Wong-Staal F.
Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982).
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Rousset M., Zweibaum A., Fogh J.
Cancer Res. 41:1165-1170(1981).
Mutations of the VHL tumour suppressor gene in renal carcinoma.";
Linehan W.M.
Nat. Genet. 7:85-90(1994).
Identification of the von Hippel-Lindau disease tumor suppressor gene.
Chinault A.C., Maher E.R., Linehan W.M., Zbar B., Lerman M.I.
Science 260:1317-1320(1993).
Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro.
Schellens J.H.M.
Cancer Chemother. Pharmacol. 41:307-316(1998).
Systematic variation in gene expression patterns in human cancer cell lines.
Botstein D., Brown P.O.
Nat. Genet. 24:227-235(2000).
Combined LOH/CGH analysis proves the existence of interstitial 3p deletions in renal cell carcinoma.
Imreh S., Klein G., Zabarovsky E.R.
Oncogene 19:1392-1399(2000).
Expression of the SART1 tumor rejection antigen in renal cell carcinoma.
Yoshizumi O., Itoh K.
Urol. Res. 28:178-184(2000).
PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines.
Nakatani Y., Hosaka M.
Int. J. Cancer 91:219-224(2001).
Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
Otterud B.E., Leppert M.F., Storb R., Sandmaier B.M.
Clin. Cancer Res. 10:7799-7811(2004).
Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with interferon-alpha in renal cell carcinoma cell lines.
Nakatani T.
Urol. Int. 73:348-353(2004).
HLA class I and II genotype of the NCI-60 cell lines.";
Morse H.C. 3rd, Stroncek D., Marincola F.M.
J. Transl. Med. 3:11.1-11.8(2005).
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mol. Cancer Ther. 5:2606-2612(2006).
Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma.
Kahnoski R., Yang X.-M.J., Teh B.T.
Cancer Res. 67:3171-3176(2007).
DNA fingerprinting of the NCI-60 cell line panel.";
Chanock S.J., Weinstein J.N.
Mol. Cancer Ther. 8:713-724(2009).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Ambudkar S.V., Gottesman M.M.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
Human tumor cell strains defective in the repair of alkylation damage.
Mattern M.R.
Carcinogenesis 1:21-32(1980).
Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.
Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.
PLoS ONE 7:E31628-E31628(2012).
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
Yoon C.N., Chang Y.-T.
PLoS ONE 7:E32096-E32096(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Science 336:1040-1044(2012).
Loss of PBRM1 expression is associated with renal cell carcinoma progression.
Pawlowski R., Muhl S.M., Sulser T., Krek W., Moch H., Schraml P.
Int. J. Cancer 132:E11-E17(2013).
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
Cancer Res. 73:4372-4382(2013).
Global proteome analysis of the NCI-60 cell line panel.";
Wilhelm M., Kuster B.
Cell Rep. 4:609-620(2013).
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Hirshfield K.M., Oltvai Z.N., Vazquez A.
Cancer Metab. 1:20.1-20.13(2013).
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
PLoS ONE 9:E92047-E92047(2014).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).